BioSpace News Archive

Olympus, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later date.

The single-cell analysis market size was estimated at USD 4.64 billion in 2023 and it is increasing up to USD 24.97 billion by 2033

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.

ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.

Crossject announces progress on multiple fronts in its clinical development, registration and U.S. commercial strategy and reports its financial results for the year ending December 31, 2023.

Swedish Orphan Biovitrum AB published its Annual and sustainability report for 2023. Inspired by caring and powered by science, the integrated report summarises business and strategy, financial performance, and work on sustainability.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on April 1, 2024 as inducements material to each employee entering into employment with KalVista.

Hexiris Inc., a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery, is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.